Answers are grounded in this paper and cite their sources.
Summary: Cytogenetics supported by additional molecular analyses and minimal residual disease detection have been successfully combined to improve the outcome of childhood acute lymphoblastic leukemia (ALL). Results from the St. Jude Total Therapy Study 16 demonstrate that some of the recently identified ALL subtypes can further guide risk stratification. See related article by Jeha et al., p. 326.
No takes yet. Share an insight, caveat, or question.
Segers et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: